Our medical device lawyers are now accepting Bard PowerPort® lawsuits for individuals injured after the port catheter fractured or pinched-off allowing pieces of the catheter to migrate into the patient’s vena cava. This can lead to serious and potentially life-threatening injuries such as infections and sepsis, blood clots, perforation of vessels, organs and tissue, pulmonary embolisms, cardiac punctures, cardiac tamponade, and bleeding.
Continue Reading about Bard PowerPort LawsuitsMain Content
Surgical Mesh
Hernia Mesh Lawsuits
People are filing thousands of lawsuits against hernia mesh manufacturers, alleging design and manufacturing defects and failure to warn of serious side effects.
Continue ReadingWeight Loss Drugs
Ozempic, Mounjaro, and Wegovy Lawsuits
Our personal injury attorneys are reviewing potential Ozempic, Mounjaro, and Wegovy lawsuits for individuals injured after taking the drugs for weight loss. Ozempic®, Mounjaro®, and Wegovy® have been linked to severe injuries like Gastroparesis (stomach paralysis), cholecystitis (inflammation of the gallbladder), cholelithiasis (gallstones), and other gastrointestinal problems.
Continue Reading about Ozempic, Mounjaro, and Wegovy LawsuitsFIRM NEWS
Bard PowerPort Lawsuits and Port a Cath Complications
August 2023 update. Bard is a medical device manufacturer that produces a variety of products, including the PowerPort® implantable port or port a cath. This device is designed to provide long-term access to the bloodstream for patients who need frequent injections or infusions of medications, fluids, or blood products. PowerPort and Port a Cath complications,… Read More
Class Action Filed Against Sweetwater Union High School District Over Data Breach
If you are a current or former employee or student, or their spouse, dependent, or family member, associated with Sweetwater Union High School District (SUHSD), you might have received one or more letters notifying you that your personal information may have been stolen in a cyberattack that occurred in February 2023.